Esketamine: A New Approach for Patients with Treatment-Resistant Depression
In 2019 the Food and Drug Administration (FDA) approved the first truly new medication for major depression in decades. The drug is a nasal spray called esketamine, derived from ketamine—an anesthetic that has made waves for its surprising antidepressant effect.
Because treatment with esketamine might be so helpful to patients with treatment-resistant depression (meaning standard treatments had not helped them), the FDA expedited the approval process to make it more quickly available. In one study, 70 percent of patients with treatment-resistant depression who were started on an oral antidepressant and intranasal esketamine improved, compared to just over half in the group that did not receive the medication.
If you want to find out if it’s right for you and your situation, give us a call and we would be happy to discuss it with you 844-727-7451. Or fill out the form below.